252 related articles for article (PubMed ID: 32441450)
41. Clinical management of Australian adolescents and young adults with acute lymphoblastic and myeloid leukemias: A national population-based study.
White VM; Skaczkowski G; Pinkerton R; Coory M; Osborn M; Bibby H; Nicholls W; Orme LM; Conyers R; Phillips MB; Harrup R; Walker R; Thompson K; Anazodo A
Pediatr Blood Cancer; 2018 Nov; 65(11):e27349. PubMed ID: 30039912
[TBL] [Abstract][Full Text] [Related]
42. Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.
Dony A; Belhabri A; Bertrand Y; Sebban C; Cony-Makhoul P; Sobh M; Rogasik M; Salles G; Anglaret B; Freycon C; Corm S; Faurie P; Cornillon J; Michallet AS; Chassagne-Clément C; Berger F; Ray-Coquard IL
J Adolesc Young Adult Oncol; 2019 Dec; 8(6):684-696. PubMed ID: 31411521
[No Abstract] [Full Text] [Related]
43. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
Pinnix CC; Osborne EM; Chihara D; Lai P; Zhou S; Ramirez MM; Oki Y; Hagemeister FB; Rodriguez AM; Samaniego F; Fowler N; Romaguera JE; Turturro F; Fayad L; Westin JR; Nastoupil L; Neelapu SS; Cheah CY; Dabaja BS; Milgrom SA; Smith GL; Horace P; Milbourne A; Wogan CF; Ballas L; Fanale MA
JAMA Oncol; 2016 Aug; 2(8):1065-9. PubMed ID: 27227654
[TBL] [Abstract][Full Text] [Related]
44. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
45. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
[TBL] [Abstract][Full Text] [Related]
46. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.
Schwartz CL; Chen L; McCarten K; Wolden S; Constine LS; Hutchison RE; de Alarcon PA; Keller FG; Kelly KM; Trippet TA; Voss SD; Friedman DL
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27786406
[TBL] [Abstract][Full Text] [Related]
47. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
[TBL] [Abstract][Full Text] [Related]
48. Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study.
Keegan TH; DeRouen MC; Parsons HM; Clarke CA; Goldberg D; Flowers CR; Glaser SL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):264-73. PubMed ID: 26826029
[TBL] [Abstract][Full Text] [Related]
49. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
50. [A single-center retrospective analysis of 85 children and adolescents with limited-stage Hodgkin lymphoma].
Wu B; Wang J; Zhu J; Zhen ZZ; Lu SY; Sun FF; Huang JT; Sun XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):649-654. PubMed ID: 32942818
[No Abstract] [Full Text] [Related]
51. Improving the prognosis of pediatric Hodgkin lymphoma in developing countries: a Moroccan Society of Pediatric Hematology and Oncology study.
Hessissen L; Khtar R; Madani A; El Kababri M; Kili A; Harif M; Khattab M; Sahraoui S; Benjaafar N; Ahid S; Howard SC; Benchekroun S
Pediatr Blood Cancer; 2013 Sep; 60(9):1464-9. PubMed ID: 23606223
[TBL] [Abstract][Full Text] [Related]
52. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
[TBL] [Abstract][Full Text] [Related]
53. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
54. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
55. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL
J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442
[TBL] [Abstract][Full Text] [Related]
56. Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.
Unger JM; Beauchemin M; Hershman DL
Cancer; 2021 Dec; 127(24):4574-4584. PubMed ID: 34351619
[TBL] [Abstract][Full Text] [Related]
57. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
[TBL] [Abstract][Full Text] [Related]
58. Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma.
Ozuah NW; Marcus KJ; LaCasce AS; Billett AL
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e338-e342. PubMed ID: 29293187
[TBL] [Abstract][Full Text] [Related]
59. AYA Considerations for Aggressive Lymphomas.
Llaurador G; Giulino-Roth L
Curr Hematol Malig Rep; 2021 Feb; 16(1):61-71. PubMed ID: 33728589
[TBL] [Abstract][Full Text] [Related]
60. Adolescent hodgkin lymphoma: are treatment results more favorable with pediatric than with adult regimens?
Müller J; Illés A; Molnár Z; Rosta A; Váróczy L; Kovács G
J Pediatr Hematol Oncol; 2011 Mar; 33(2):e60-3. PubMed ID: 21285900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
